Environmental

CRIS appears below diversified biotech peers on environmental disclosure depth, as the provided metrics emphasize R&D intensity rather than emissions, energy, or waste management transparency.

The company’s small balance-sheet leverage reduces environmental transition pressure versus more capital-intensive peers, but it does not itself indicate stronger operational sustainability performance.

No Tier 1 filing evidence in the prompt shows formal climate targets, renewable-energy commitments, or supply-chain environmental controls, leaving its relative positioning difficult to distinguish.

Because the business model is research-led and asset-light, environmental risk is likely less structurally material than for manufacturing peers, yet disclosure remains comparatively limited.

Social

High R&D spending relative to revenue suggests sustained scientific investment, which can support employee expertise and patient-facing innovation versus lower-investment peers.

Stock-based compensation is elevated relative to revenue, which may aid retention in a specialized talent market, but it also signals heavier dilution pressure than better-aligned peers.

The prompt provides no evidence on clinical-trial conduct, product safety, diversity, or community engagement, so social positioning cannot be assessed as stronger than peers.

Overall social performance appears mixed, with human-capital intensity supportive but insufficient disclosure preventing a clear advantage over peer companies.

Governance

Low debt-to-equity and net-debt-to-EBITDA ratios indicate restrained financial leverage, which generally lowers governance risk versus more indebted peers.

Very high gross margin and modest leverage suggest capital discipline, but the provided metrics do not show board independence, audit quality, or shareholder-rights strength.

Stock-based compensation at nearly 0.4x revenue is a notable governance drag relative to peers with tighter dilution control, even if not structurally impairing.

Without filing-based evidence on controls, related-party practices, or executive oversight, governance appears adequate but not clearly superior to peer standards.

Overall Score

CRIS shows a modestly supportive ESG profile driven by low leverage and research intensity, but limited disclosure and elevated compensation dilution keep it near peer average.

Score Driver: Limited Tier 1 ESG Disclosure Relative To Peers